4/3/2023 0 Comments Htn better blockerAs compared to angiotensin receptor blockers (ARBs), CCBs reduced myocardial infarction (RR 0.82, 95% CI 0.72 to 0.94, moderate‐certainty evidence) and increased congestive heart failure (RR 1.20, 95% CI 1.06 to 1.36, low‐certainty evidence). As compared to angiotensin‐converting enzyme (ACE) inhibitors, CCBs reduced stroke (RR 0.90, 95% CI 0.81 to 0.99, low‐certainty evidence) and increased congestive heart failure (RR 1.16, 95% CI 1.06 to 1.28, low‐certainty evidence). As compared to beta‐blockers, CCBs reduced the following outcomes: major cardiovascular events (RR 0.84, 95% CI 0.77 to 0.92), stroke (RR 0.77, 95% CI 0.67 to 0.88, moderate‐certainty evidence), and cardiovascular mortality (RR 0.90, 95% CI 0.81 to 0.99, low‐certainty evidence). As compared to diuretics, CCBs probably increased major cardiovascular events (risk ratio (RR) 1.05, 95% confidence interval (CI) 1.00 to 1.09, P = 0.03) and increased congestive heart failure events (RR 1.37, 95% CI 1.25 to 1.51, moderate‐certainty evidence). All‐cause mortality was not different between first‐line CCBs and any other antihypertensive classes. We included a total of 23 RCTs (18 dihydropyridines, 4 non‐dihydropyridines, 1 not specified) with 153,849 participants with hypertension. We contacted study authors for additional information. Any disagreements were resolved through discussion. Three review authors independently selected the included trials, evaluated the risk of bias, and entered the data for analysis. Randomised controlled trials comparing first‐line CCBs with other antihypertensive classes, with at least 100 randomised hypertensive participants and a follow‐up of at least two years. The searches had no language restrictions. We also contacted the authors of relevant papers regarding further published and unpublished work and checked the references of published studies to identify additional trials. Search methodsįor this updated review, the Cochrane Hypertension Information Specialist searched the following databases for randomised controlled trials (RCTs) up to 1 September 2020: the Cochrane Hypertension Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL 2020, Issue 1), Ovid MEDLINE, Ovid Embase, the World Health Organization International Clinical Trials Registry Platform, and. To determine whether CCBs used as first‐line therapy for hypertension are different from other classes of antihypertensive drugs in reducing the incidence of major adverse cardiovascular events. While calcium channel blockers (CCBs) are often recommended as a first‐line drug to treat hypertension, the effect of CCBs on the prevention of cardiovascular events, as compared with other antihypertensive drug classes, is still debated. This is the first update of a review published in 2010.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |